Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of chronic hepatitis C therapy in community-based trials.
Marotta P, Hueppe D, Zehnter E, Kwo P, Jacobson I. Marotta P, et al. Among authors: hueppe d. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1028-36; quiz 1022. doi: 10.1016/j.cgh.2009.05.003. Epub 2009 May 15. Clin Gastroenterol Hepatol. 2009. PMID: 19447199 Review.
Expert opinion on the treatment of patients with chronic hepatitis C.
Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E, Manns MP. Zeuzem S, et al. Among authors: hueppe d. J Viral Hepat. 2009 Feb;16(2):75-90. doi: 10.1111/j.1365-2893.2008.01012.x. Epub 2008 Aug 28. J Viral Hepat. 2009. PMID: 18761607 Free PMC article. Review.
Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
Mauss S, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Link R, Teuber G, Herrmann A, Spelter M, Wollschlaeger S, Baumgarten A, Simon KG, Dikopoulos N, Witthoeft T. Mauss S, et al. Among authors: hueppe d. J Viral Hepat. 2011 Apr;18(4):e81-90. doi: 10.1111/j.1365-2893.2010.01372.x. Epub 2010 Sep 16. J Viral Hepat. 2011. PMID: 20849436
Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study.
Witthoeft T, Hueppe D, John C, Goelz J, Heyne R, Moeller B, Teuber G, Wollschlaeger S, Baumgarten A, Simon KG, Moog G, Dikopoulos N, Mauss S. Witthoeft T, et al. Among authors: hueppe d. J Viral Hepat. 2010 Jul;17(7):459-68. doi: 10.1111/j.1365-2893.2009.01255.x. Epub 2010 Feb 11. J Viral Hepat. 2010. PMID: 20158603
Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, Galle PR, Alshuth U. Zimmermann T, et al. Among authors: hueppe d. J Gastrointestin Liver Dis. 2016 Mar;25(1):15-24. doi: 10.15403/jgld.2014.1121.251.a2a. J Gastrointestin Liver Dis. 2016. PMID: 27014750 Free article. Clinical Trial.
Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?
Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Bischoff J, et al. Among authors: hueppe d. J Clin Gastroenterol. 2020 Feb;54(2):192-199. doi: 10.1097/MCG.0000000000001189. J Clin Gastroenterol. 2020. PMID: 30789853
Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Wehmeyer MH, et al. Among authors: hueppe d. J Med Virol. 2018 Feb;90(2):304-312. doi: 10.1002/jmv.24903. Epub 2017 Nov 9. J Med Virol. 2018. PMID: 28710853
20 results